Overview

Biodesix was founded in 2005 tofrost award apply the principles of complex data analysis and mass spectrometry (MS) to the discovery and development of improved multivariate tests that give physicians better information to understand the patient and their disease. Understanding the clinically meaningful information contained within each patient’s molecular profile may improve diagnosis and therapeutic intervention and lead to better outcomes.  We have demonstrated leadership in personalizing medicine by introducing VeriStrat®, the first serum proteomic test for advanced non-small cell lung cancer patients that helps physicians determine if a patient should receive treatment with erlotinib (Tarceva ®), an epidermal growth factor inhibitor.

To enable the reliable use of MS for analysis of patient samples, Biodesix scientists developed ProTS®, a proprietary technology platform that harnesses the power of mass spectrometry and provides the unparalleled ability to analyze and compare complex data sets.  ProTS enables the rapid discovery and validation of diagnostic tests that answer a wide range of clinical questions.  Because we understand the challenges of obtaining sufficient and representative biological material, our tests are also designed to be non-invasive, requiring minimal amounts of readily accessible biological fluids, such as blood or serum.

Biodesix collaborates with leading researCO-companies-to-watchchers and builds strategic partnerships with biotechnology and pharmaceutical companies to develop companion diagnostics and build our pipeline of new products.

Biodesix’ research and development activities are conducted with the highest clinical integrity, including external validation with medical experts and properly designed and controlled clinical trials. Our internal controls are designed to ensure compliance with applicable federal, state, and local statutes and regulations relevant to providers of healthcare services.